Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
18 January 2023

ORYZON announces First Patient In in NET, a collaborative Phase II basket study with iadademstat in R/R patients with neuroendocrine carcinomas

24 January 2023

Invest Securities Biomed Forum 2023

Paris

France

9-12 January 2023

41st Annual J.P. Morgan Healthcare Conference

Westin St. Francis Hotel, San Francisco

CA

United States

9-11 January 2023

12th Annual LifeSci Advisors Corporate Access Event

Beacon Grand Hotel, San Francisco

CA

United States

8 January 2023

6th Sachs Annual Neuroscience Innovation Forum

Marine’s Memorial Club, San Francisco

CA

United States

5 January 2023

ORYZON to give updates on corporate progress in January

16 December 2022

ORYZON awarded EU grant to further explore the role of iadademstat in oncological immunotherapy approaches

12 December 2022

ORYZON presents final data from Phase IIa ALICE trial in unfit AML patients with first-line treatment of iadademstat and azacitidine in oral presentation at ASH-2022

10-13 December 2022

64th American Society of Hematology (ASH) Annual Meeting and Exposition

New Orleans

LA

United States

9 November 2022

ORYZON announces FDA clearance of IND to initiate a collaborative Phase II basket study with iadademstat in R/R patients with Neuroendocrine carcinomas (NECs)

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Current page 18
  • Page 19
  • Page 20
  • Page 21
  • Page 22
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel